Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1637715 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $3.95Day +0.00%Mkt cap $160M1Y +74.8%Off 52W high −26.6%Vol (1Y) 74.8%
Daily closing price, split-adjusted to the current basis; 1.8y shown of 443 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest2.9% of sh out |
| Days to cover5.8d |
| 13F net flow (QoQ)+11.78% |
| Top-10 13F concentration82.4% |
| Next report (est.)2026-08-08 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$58.7M |
| ROE−74.4% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+36.2% |
| 1Y+74.8% |
| Since incept. (ann.)−57.6% |
Total return through 2026-07-29 · series begins 2024-10-07. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)74.8% |
| Ann. volatility (3Y)72.4% |
| Sharpe (1Y)1.13 |
| Sharpe (3Y)−0.86 |
| Max drawdown (1Y)−41.6% |
| Max drawdown (3Y)−90.5% |
| Beta (3Y vs SPY)0.71 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 4.0M | $17M | 9.90% | new |
| ACORN CAPITAL ADVISORS, LLC | 2.8M | $12M | 7.03% | +0.0% |
| StepStone Group LP | 2.7M | $11M | 6.59% | +440.8% |
| ADAR1 Capital Management, LLC | 2.4M | $10M | 6.03% | +140.1% |
| Prosight Management, LP | 2.2M | $9M | 5.33% | +163.7% |
| BVF INC/IL | 2.0M | $8M | 4.90% | new |
| Vivo Capital, LLC | 1.9M | $8M | 4.77% | new |
| Vestal Point Capital, LP | 1.8M | $8M | 4.55% | +189.7% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-05 | −$1.11 | — | — | — |
| 2025-09-30 | 2025-11-06 | −$1.09 | — | — | — |
| 2025-06-30 | 2025-08-12 | −$1.14 | — | — | — |
| 2025-03-31 | 2025-05-06 | −$1.19 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-08 is ESTIMATED from filing cadence (median gap 95d) — not company-confirmed.
